Kasr El Aini Hospital
Cairo, 11562, Egypt
NCT Number: NCT03637101
In the current study the investigators intend to evaluate the role of Ischemia modified albumin (IMA) in the prediction of poor outcome in patients with traumatic brain injury (TBI). The investigators hypothesize that IMA will be elevated in patients with traumatic brain injury due to the excessive production of reactive oxygen species by the injured brain.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Cairo, 11562, Egypt
Consecutive adult patients who were admitted with TBI, blood samples were taken once written informed consent obtained. Initial evaluation on admission was performed simultaneously by ICU physician and a neurosurgical resident by means of a detailed physical and neurological examination. Demographic characteristics and vascular risk factors (hypertension, diabetes mellitus, hyperlipidemia, and peripheral ischemic disease) were recorded in details. Also, Routine blood tests, including full blood count, coagulation tests, glucose level, renal and hepatic function tests, total protein, and albumin levels; chest radiography were done.
CT scan will be performed in all the cases for the confirmation of TBI. Glasgow coma scale (GCS) was assessed on admission and recorded and assessed daily to evaluate prognosis. Patients were monitored by BP, ECG, and Pulse oximetry. All patients received standard medical treatment which included anti-edema measures mannitol 20%, 0.25-0.5 g/kg over 20 min, (not exceeding a total of 2 g/kg of body weight in 24 h) in patients with symptoms of raised intracranial pressure, and other supportive therapy for the treatment of concurrent illnesses such as hypertension and diabetes mellitus.
Biochemical Assessments:
Blood samples from TBI patients were collected immediately at the time of admission to the ICU and 24 hours later. Samples were centrifuged at 2500 RPM for 15 minutes and obtained serum samples were stored at -20oC.
IMA was measured by the colorimetric method and results were presented in absorbance units (ABSU).
Data collection
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Ischemia modified albumin is a biomarker for cardiac ischemia and acute stroke whether ischemic or hemorrhagic
Time frame: The number of patients who died within 28 days from admission to ICU after TBI and who were investigated for IMA upon admission to ICU
IMA in ng/ml will be measured at time of admission to ICU and correlated with 28 day mortality
Time frame: The number of patients who died within 28 days from admission to ICU after TBI and who were investigated for IMA 24 hours after admission to ICU
IMA in ng/ml will be measured 24 hours after admission to ICU and correlated with 28 day mortality
Time frame: IMA on admission to ICU and after 24 hours
The percentage of patients having elevated IMA in ng/ml from the recruited patients with traumatic brain injuries.
Time frame: Glasgow coma scale immediately on admission to the ICU, IMA will be collected on admission to ICU and after 24 hours
The severity of traumatic brain injury classified by Glasgow Coma Scale as mild 13-15, moderate 9-12 or severe 3-8 and the IMA levels in ng/ml in those patients.
Time frame: The number of days in ICU till discharge or mortality up to 28 days post admission
The number of days spent in ICU for patients with mild TBI (GCS 13-15)
Time frame: The number of days in ICU till discharge or mortality up to 28 days post admission
The number of days spent in ICU for patients with moderate TBI (GCS 9-12)
Time frame: The number of days in ICU till discharge or mortality up to 28 days post admission
The number of days spent in ICU for patients with severe TBI (GCS 3- 8)
Time frame: Glasgow coma scale immediately on admission to the ICU and daily till mortality or discharge up to 28 days post admission
The severity of traumatic brain injury classified by Glasgow Coma Scale as mild 13-15, moderate 9-12 or severe 3-8 on admission and the Glasgow coma scale on the following days in the ICU til mortality or discharge
Kasr El Aini Hospital
Other
Ischemia Modified Albumin as a Biomarker for Prediction of Poor Outcome in Patients With Traumatic Brain Injury. Observational Cohort Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01287156
Brain Diseases, Brain Injuries
Washington D.C., District of Columbia, United States
View Trial DetailsNCT05714150
Brain Diseases, Brain Injuries
Gainesville, Florida, United States
View Trial DetailsNCT04056312
Brain Diseases, Brain Injuries
West Orange, New Jersey, United States
View Trial DetailsNCT01132937
Brain Diseases, Brain Injuries
Bethesda, Maryland, United States
View Trial Details